Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Interest Expenses (2023)

Contineum Therapeutics has reported Interest Expenses over the past 1 years, most recently at $116000.0 for Q2 2023.

  • Quarterly results put Interest Expenses at $116000.0 for Q2 2023, changed N/A from a year ago — trailing twelve months through Mar 2024 was $116000.0 (changed N/A YoY), and the annual figure for FY2023 was $208000.0, changed.
  • Interest Expenses for Q2 2023 was $116000.0 at Contineum Therapeutics, up from $92000.0 in the prior quarter.
  • Over the last five years, Interest Expenses for CTNM hit a ceiling of $116000.0 in Q2 2023 and a floor of $92000.0 in Q1 2023.